Ocular Therapeutix, Inc. (OCUL) financial statements (2021 and earlier)

Company profile

Business Address 24 CROSBY DRIVE
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5454426810575
Cash and cash equivalents545442333137
Short-term investments   357437
Receivables300000
Inventory, net of allowances, customer advances and progress billings100000
Inventory100000
Deferred costs  0   
Other undisclosed current assets221121
Total current assets:6056437010776
Noncurrent Assets
Operating lease, right-of-use asset7
Property, plant and equipment101010332
Restricted cash and investments272200
Total noncurrent assets:191712532
TOTAL ASSETS:7973557511078
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1198756
Accounts payable334221
Accrued liabilities864533
Employee-related liabilities     1
Debt1 62 1
Deferred revenue and credits  00
Other undisclosed current liabilities     (1)
Total current liabilities:12913856
Noncurrent Liabilities
Long-term debt and lease obligation582512141514
Long-term debt, excluding current maturities492512141514
Operating lease, liability9
Liabilities, other than long-term debt1233100
Deferred revenue and credits33100
Derivative instruments and hedges, liabilities12     
Total noncurrent liabilities:702816151514
Total liabilities:823729232119
Stockholders' equity
Stockholders' equity attributable to parent(4)3626529059
Common stock000000
Additional paid in capital380333263226219148
Accumulated other comprehensive loss   (0)(0) 
Accumulated deficit(384)(297)(237)(174)(129)(89)
Total stockholders' equity:(4)3626529059
TOTAL LIABILITIES AND EQUITY:7973557511078

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues422221
Revenue, net2221
Cost of revenue(2)(0)(0)(0)(0)(0)
Cost of goods and services sold(2) (0)(0)(0)(0)
Gross profit:221111
Operating expenses(88)(61)(63)(45)(40)(28)
Other undisclosed operating income    00
Operating loss:(86)(59)(62)(43)(38)(27)
Nonoperating expense(1)(1)(1)(1)(2)(2)
Investment income, nonoperating110000
Other nonoperating income (expense)(0) 0(0)0(0)
Interest and debt expense(6)(2)(2)(2)(2)(1)
Loss before gain (loss) on sale of properties:(92)(62)(65)(46)(41)(30)
Other undisclosed net income1792    
Net income (loss):86(60)(65)(46)(41)(30)
Other undisclosed net income (loss) attributable to parent(173) 2221
Net loss attributable to parent:(86)(60)(63)(45)(40)(29)
Preferred stock dividends and other adjustments     (0)
Net loss available to common stockholders, diluted:(86)(60)(63)(45)(40)(29)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):86(60)(65)(46)(41)(30)
Comprehensive income (loss):86(60)(65)(46)(41)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(173) 222 
Comprehensive loss, net of tax, attributable to parent:(86)(60)(63)(45)(40)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: